Genocea starts work on chlamydia vax; Pfizer wins vax approval

Vaccine Research

Genocea Biosciences has won a grant to work on a new chlamydia vaccine. Genocea release

San Diego start-up Pfenex has inked a $52 million deal to license its technology to Merck.  Story

Merck KGaA has started another late-stage trial of stimuvax, a cancer vaccine it licensed from Oncothyreon. Release

Shares of Intercell were fired up by news that GlaxoSmithKline is backing the company with a sizeable upfront and a hefty equity payment as it takes a stake in the Austrian biotech's needle-free vaccine patch technology. Story

H1N1

The second wave of swine flu may have peaked in the U.S. and the Northern Hemisphere, but World Health Organization officials say it's too early to declare the pandemic over. Story

With supplies of the H1N1 vaccine growing in the U.S., giant drugstore chain Walgreen says it will have the vaccine available throughout the country by the end of this year. Other chains are in hot pursuit. Report

Sanofi-Aventis is trying to reclaim up to 800,000 doses of swine flu vaccine that is less potent than required. Most of it has already been used, health officials say, and even the weakened dose is likely to provide protection. Story

Vaccine Market

Pfizer has won approval in Europe for its upgraded children's pneumococcal vaccine, Prevenar 13. Story

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.